![Dragan Grabulovski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dragan Grabulovski
Chief Executive Officer at Araris Biotech AG
Profile
Dragan Grabulovski was the founder of Covagen AG, a company founded in 2007 where he held the title of Wissenschaftler from 2007 to 2009.
He is also the founder of Araris Biotech AG, a company founded in 2019 where he currently holds the titles of Chairman & Chief Executive Officer.
In addition to his founding positions, Dr. Grabulovski currently holds the position of Director, Head-Business Development & Strategy at Memo Therapeutics AG.
He also serves as a Venture Partner at Pureos Partners AG since 2021.
Dr. Grabulovski's education includes undergraduate and doctorate degrees from the Swiss Federal Institute of Technology.
Dragan Grabulovski active positions
Companies | Position | Start |
---|---|---|
Araris Biotech AG
![]() Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | Chief Executive Officer | 2023-10-03 |
Memo Therapeutics AG
![]() Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Private Equity Investor | 2021-08-31 |
Former positions of Dragan Grabulovski
Companies | Position | End |
---|---|---|
Covagen AG
![]() Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Founder | - |
Training of Dragan Grabulovski
Swiss Federal Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Covagen AG
![]() Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
Memo Therapeutics AG
![]() Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
Pureos Partners AG
![]() Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Finance |
Araris Biotech AG
![]() Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | Commercial Services |
- Stock Market
- Insiders
- Dragan Grabulovski